News


All series


All News

The International Vision Expo and Conference East will celebrate its 25th year March 16-20 at the Jacob K. Javits Convention Center, New York City.

An age-adjusted retinal nerve fiber layer thickness normative database for a proprietary ocular coherence tomography device gives clinicians a tool for assessing glaucoma risk from a patient's first visit.

Pooled results from two prospective, multicenter, double-masked, placebo-controlled studies show a multimodal anti-allergy product, bepotastine besilate ophthalmic solution 1.5%, provides rapid and long-lasting clinically significant improvement in allergen-induced ocular itching.

Olopatadine hydrochloride ophthalmic solution 0.2%, a combination mast cell stabilizer and antihistamine, effectively relieves the itching associated with allergic conjunctivitis with once-daily dosing.

Results of an in vitro study of the potentially adverse effects of different topical glaucoma medications and preservatives showed that the preservatives polyquad and sofZia had much less toxicity when used in place of benzalkonium chloride in prostaglandin analog formulations.

A growing body of evidence points to diurnal fluctuations in intraocular pressure and nocturnal low ocular perfusion pressure as risk factors in the development and progression of glaucoma.

Factors as disparate as ocular blood flow, beta blockers, and sleep apnea all may play roles in the development and progression of glaucoma.